InDex Pharmaceuticals Holding AB (FLERIE) AI Stock Analysis

• Market Cap: kr3.47B
• Dividend Yield: N/A
• Average Volume (3M): 36.39K
• Price to Earnings (P/E): 0.3
• Beta (1Y): -0.04
• Revenue Growth: -75.91%
• EPS Growth: N/A
• Country: SE
• Employees: 8
• Sector: Healthcare
• Sector Strength: 42
• Industry: Drug Manufacturers - General
• EPS (TTM): -3.21
• Shares Outstanding: 78,066,410
• 10 Day Avg. Volume: 8,180
• 30 Day Avg. Volume: 36,388
• PEG Ratio: 0.05
• Price to Book (P/B): 0.91
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.37K
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: kr45.04
• Price Target Upside: -3.96% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 50 Neutral
• Price Target: kr45.00 ▼(-4.05%Downside)

The stock's overall score is primarily driven by financial performance challenges, including negative profitability and cash flow, despite a stable balance sheet. Technical analysis suggests slight bullish momentum, but valuation concerns due to a very low P/E ratio and lack of dividend yield present significant risks.

InDex Pharmaceuticals Holding AB Business Overview & Revenue Model

Company Description

InDex Pharmaceuticals Holding AB (FLERIE) is a pharmaceutical company focused on the development of treatments for immunological diseases. The company's primary focus is on its lead product candidate, cobitolimod, designed to treat moderate to severe ulcerative colitis, a chronic inflammatory bowel disease. InDex Pharmaceuticals operates in the biotechnology sector, aiming to address unmet medical needs through innovative therapies.

How the Company Makes Money

InDex Pharmaceuticals generates revenue primarily through the development and commercialization of its proprietary pharmaceutical products. The company aims to monetize its lead product, cobitolimod, through partnerships, licensing agreements, and potential direct sales upon achieving regulatory approvals. Key revenue streams include milestone payments and royalties from strategic partnerships with larger pharmaceutical companies that may help distribute and market the drug globally. Additionally, the company might receive funding and grants from medical research institutions and government bodies supporting drug development initiatives.

InDex Pharmaceuticals Holding AB Financial Statement Overview

Summary

The company faces significant challenges in profitability and cash flow, typical of emerging biotechnology firms. While the balance sheet reflects strong equity and low leverage, the income statement and cash flow statement reveal operational difficulties. Continued dependence on external financing may pose a risk if revenue generation does not improve.

Income Statement

The company has struggled with profitability, as evidenced by negative EBIT and net income. The gross profit margin is nonexistent with consistently negative gross profit. Revenue growth is stagnant, with minimal revenue in recent years. These factors indicate significant challenges in operational efficiency and market penetration.

Balance Sheet

The company maintains a strong equity position with a high equity ratio, indicating financial stability. The debt-to-equity ratio is minimal, suggesting low leverage and reduced financial risk. However, asset growth has not been matched by revenue growth, which could indicate inefficiencies in asset utilization.

Cash Flow

Operating and free cash flows are persistently negative, highlighting cash flow challenges. The high financing cash flow suggests reliance on external funding, which may not be sustainable long-term. The operating cash flow to net income ratio is poor, indicating inefficiencies in converting earnings into cash.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	100.00K	97.50M	0.00	0.00	35.00K
Gross Profit	-41.60M	93.35M	-1.07M	-1.25M	-57.73M
EBITDA	-225.90M	-93.82M	-99.15M	-101.66M	-56.11M
Net Income	-228.00M	-95.27M	-100.33M	-103.04M	-57.42M
Balance Sheet
Total Assets	4.22B	299.39M	351.34M	445.20M	61.18M
Cash, Cash Equivalents and Short-Term Investments	865.10M	294.27M	344.93M	428.45M	53.83M
Total Debt	800.00K	2.30M	3.25M	1.28M	2.34M
Total Liabilities	25.30M	60.50M	17.38M	11.16M	11.86M
Stockholders Equity	4.20B	238.88M	333.96M	434.04M	49.33M
Cash Flow
Free Cash Flow	-17.00M	-37.98M	-129.44M	-124.06M	-71.56M
Operating Cash Flow	-17.00M	-37.98M	-129.44M	-124.06M	-70.65M
Investing Cash Flow	-19.80M	-625.20M	0.00	0.00	-909.00K
Financing Cash Flow	571.90M	634.70M	-818.00K	486.39M	-1.40M

InDex Pharmaceuticals Holding AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 46.90
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:FLERIE, the sentiment is Negative. The current price of 46.9 is above the 20-day moving average (MA) of 46.16, above the 50-day MA of 45.31, and above the 200-day MA of 45.40, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 39.28 is Neutral, neither overbought nor oversold. The STOCH value of 2.08 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:FLERIE.

InDex Pharmaceuticals Holding AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$7.35B	-0.07	-63.71%	2.36%	16.17%	0.03%
FLERIE	50 Neutral	kr3.47B	0.29	-15.21%	―	-75.91%	―
SYNACT	48 Neutral	kr1.09B	―	-48.22%	―	―	67.70%
XSPRAY	47 Neutral	kr1.91B	―	-42.24%	―	―	-19.44%
BINV	46 Neutral	kr2.51B	―	-45.80%	―	-0.57%	-39.92%
VICO	45 Neutral	kr1.83B	―	-40.15%	―	―	63.85%
HNSA	44 Neutral	kr2.21B	―		―	20.12%	40.54%